Compensatory epistasis maintains ACE2 affinity in SARS-CoV-2 Omicron BA.1

Received: 8 September 2022
Accepted: 26 October 2022
Published online: 16 November 2022

The Omicron BA.1 variant emerged in late 2021 and quickly spread across the world. Compared to the earlier SARS-CoV-2 variants, BA.1 has many mutations, some of which are known to enable antibody escape. Many of these antibody-escape mutations individually decrease the spike receptor-binding domain (RBD) affinity for ACE2, but BA.1 still binds ACE2 with high affinity. The fitness and evolution of the BA.1 lineage is therefore driven by the combined effects of numerous mutations. Here, we systematically map the epistatic interactions between the 15 mutations in the RBD of BA.1 relative to the Wuhan Hu-1 strain. Specifically, we measure the ACE2 affinity of all possible combinations of these 15 mutations \(2^{15} = 32,768\) genotypes, spanning all possible evolutionary intermediates from the ancestral Wuhan Hu-1 strain to BA.1. We find that immune escape mutations in BA.1 individually reduce ACE2 affinity but are compensated by epistatic interactions with other affinity-enhancing mutations, including Q498R and N501Y. Thus, the ability of BA.1 to evade immunity while maintaining ACE2 affinity is contingent on acquiring multiple interacting mutations. Our results implicate compensatory epistasis as a key factor driving substantial evolutionary change for SARS-CoV-2 and are consistent with Omicron BA.1 arising from a chronic infection.

The Omicron BA.1 variant of SARS-CoV-2 emerged in November 2021 and spread rapidly throughout the world, driven in part by its ability to escape existing immunity in vaccinated and previously infected individuals. Strikingly, Omicron did not emerge as a descendant of the then-widespread Delta lineage. Instead, it appeared as a highly diverged strain after accumulating dozens of mutations within a lineage that was not widely circulating at the time, including 15 mutations within the spike protein receptor-binding domain (RBD).

Recent work has shown that a number of these 15 RBD mutations (some of which are seen in other variants) disrupt binding of specific monoclonal antibodies, potentially contributing to immune escape. However, most of these mutations have also been shown to reduce binding affinity to human ACE2 when they arise within the Wuhan Hu-1.
The Tite-Seq measurements are highly reproducible (SEM of 0.2 log $K_{D,app}$). Vertical blue and red lines indicate the $-\log K_{D,app}$ for Wuhan Hu-1 and Omicron BA.1, respectively. B Distributions of the effect of each mutation on ACE2 affinity (defined as the change in $-\log K_{D,app}$ resulting from mutation) across all possible genetic backgrounds at the other 14 loci. Black line segments indicate 25th and 75th percentiles of the effect distributions and points represent distribution means, n=16384 backgrounds. Blue and red points specify effects on Wuhan Hu-1 and most-mutated backgrounds, respectively. C Distribution of binding affinities grouped by number of Omicron BA.1 mutations. Binding affinity of the Wuhan Hu-1 variant is indicated by horizontal dashed line. The boxes correspond to the range between 25th and 75th percentiles, and the whiskers extend to the largest/smallest value no further than 1.5 times the inter-quartile range.

Delta, or several other SARS-CoV-2 lineages\textsuperscript{5,8}, potentially impairing viral entry into host cells. In contrast, the Omicron RBD tolerates these escape mutations while retaining strong affinity to ACE2\textsuperscript{10,11}, suggesting that other mutations in this lineage may help maintain viral entry.

Earlier work has systematically analyzed mutational effects on antibody binding and ACE2 affinity, for example by using deep mutational scanning (DMS)\textsuperscript{9,12}. However, these approaches focus on the effects of single mutations on specific genetic backgrounds. They are therefore useful for understanding the first steps of evolution from existing variants but cannot explain how multiple mutations interact over longer evolutionary trajectories. Thus, it remains unclear how combinations of mutations, such as those observed in Omicron, interact to both evade immunity and retain strong affinity to ACE2. To address this question, we used a combinatorial assembly approach to construct a plasmid library containing all possible combinations of the 15 mutations in the Omicron BA.1 RBD (a total of $2^{15} = 32,768$ variants). This library, which represents the largest combinatorially complete library of a viral protein to date, includes all possible evolutionary intermediates between the Wuhan Hu-1 and Omicron BA.1 RBD. We transformed this plasmid library into a standard yeast display strain, creating a yeast library in which each cell displays a single monomeric RBD variant corresponding to the plasmid in that cell. We then used Tite-Seq, a high-throughput flow cytometry and sequencing-based method\textsuperscript{13,14} (see “Methods”; Supplementary Fig. 1A), to measure the binding affinities, $K_{D,app}$, of all 32,768 RBD variants to human ACE2 in parallel.

Results and discussion

Consistent with earlier work by ourselves\textsuperscript{15} and others\textsuperscript{10,11,13}, we find that the Tite-Seq measurements are highly reproducible (SEM of 0.2 log $K_{D,app}$ between triplicate measurements) and consistent with independent low-throughput measurements (see “Methods”; Supplementary Fig. 1B–F). We note that our binding affinity measurements have small systemic differences from an earlier study\textsuperscript{7} due to differences in gating strategies, but relative affinities are consistent between the two datasets (Supplementary Fig. 1F). In addition, we find minimal variation in RBD expression levels and are thus able to infer $K_{D,app}$ for the entire combinatorial library (see “Methods”; Supplementary Fig. 3).

We find that all 32,768 RBD intermediates between Wuhan Hu-1 and Omicron BA.1 have detectable affinity to ACE2, with $K_{D,app}$ ranging between 0.1 pM and 0.1 nM (Fig. 1A and Supplementary Fig. 1; see https://desai-lab.github.io/wuhan_to_omicron/ for an interactive data browser). Consistent with previous studies\textsuperscript{10}, the BA.1 RBD exhibits a slight (threefold both by Tite-seq and by isogenic measurements) improvement in binding affinity compared to Wuhan Hu-1 (Supplementary Fig. 2). However, most (~60%) of the intermediate RBD sequences actually show a weaker binding affinity to ACE2 than the ancestral Wuhan Hu-1 RBD. In fact, there are no paths from Wuhan Hu-1 to Omicron BA.1 that do not contain at least one step that decreases ACE2 affinity. This is mainly because the vast majority of BA.1 mutations have a neutral or deleterious effect on ACE2 affinity if few other mutations are present but tend to become neutral or even beneficial in the presence of multiple other mutations (Fig. 1C; Supplementary Fig. 4). Consistent with this, we find that although most of the 15 RBD mutations reduce ACE2 affinity in the Wuhan Hu-1 background (and in many cases across most other backgrounds as well), they all become less deleterious or even beneficial in the most-mutated background.

Fig. 1 | Binding affinity landscape. a Distribution of binding affinities to ACE2 across all N=32,768 RBD genotypes tested. Binding affinities are shown as $-\log K_{D,app}$. Vertical blue and red lines indicate the $-\log K_{D,app}$ for Wuhan Hu-1 and Omicron BA.1, respectively. b Distributions of the effect of each mutation on ACE2 affinity (defined as the change in $-\log K_{D,app}$ resulting from mutation) across all possible genetic backgrounds at the other 14 loci. Black line segments indicate 25th and 75th percentiles of the effect distributions and points represent distribution means, n=16384 backgrounds. Blue and red points specify effects on Wuhan Hu-1 and most-mutated backgrounds, respectively. c Distribution of binding affinities grouped by number of Omicron BA.1 mutations. Binding affinity of the Wuhan Hu-1 variant is indicated by horizontal dashed line. The boxes correspond to the range between 25th and 75th percentiles, and the whiskers extend to the largest/smallest value no further than 1.5 times the inter-quartile range.
This pattern explains why the BA.1 RBD has a stronger affinity for ACE2 despite containing so many mutations that individually reduce ACE2 affinity: their deleterious effects are mitigated by compensatory epistatic interactions with other mutations.

To systematically analyze mutational effects and interactions, we fit a standard biochemical model of epistasis to our data. This decomposes our measured -log(KD,app) (which is expected to be proportional to the free energy of binding, ΔG) into a sum of effects from single mutations, pairwise epistasis, and higher-order epistatic interactions among larger sets of mutations (truncated at fifth order; Supplementary Fig. 5, see “Methods”). Specifically, we write the binding affinity of a sequence s as

\[ \log K_{D,s} = \beta_0 + \sum_{i=1}^{K} \sum_{c \subseteq C_i} \beta_c x_{c,s} \]  

where \( C_i \) contains all \( \binom{L}{i} \) combinations of \( i \) mutations and \( x_{c,s} \) is equal to 1 if the sequence contains all the mutations in \( c \) and to 0 otherwise.

(see Methods; all coefficients for \( c \) with \( i \) mutations are referred to as \( i^{th} \)-order coefficients). This model yields coefficients that are comparable to alternative models of statistical (Supplementary Fig. 6) and global epistasis. Generally, we find that the magnitudes of the first-order effects of individual mutations (Fig. 2a) correlate with the ACE2 contact surface area of the corresponding residue (Fig. 2b, c), and neighboring residues are more likely to have strong pairwise interactions (Fig. 2e), as we might expect from previous work.

Our inferred pairwise and higher-order coefficients reveal that strong compensatory interactions offset the effects of affinity-reducing mutations (Fig. 2d). The magnitude of these interactions is comparable to that of the first-order effects, and this epistasis is overwhelmingly positive, as excluding epistatic terms leads to a consistent underestimate of the predicted affinity (Supplementary Fig. 8). This strong positive epistasis means that mutations which reduce ACE2 affinity become less deleterious in backgrounds containing other mutations. For example, the negative first-order effect of Q498R is fully reversed by its interaction with nearby mutation N501Y; this

**Fig. 2** | Linear and epistatic effects of mutations. a First-order effects in best-fitting epistatic interaction model (up to fifth order). Error bars represent standard errors from the model fit, and are centered on the mean, n=16,384. b Co-crystal structure of Omicron BA.1 RBD and ACE2 receptor (PDB ID 7WPB). Mutated residues shown as spheres colored as in (a). c First-order effects for each mutation plotted against contact surface area between corresponding BA.1 RBD residue and ACE2. Mutations colored as in (a). The Spearman’s rank correlation coefficient (r_s) between first-order effect and contact surface area is indicated in the top-left.

d Second-order epistatic interaction coefficients and higher order interaction coefficients. For each mutation, higher order interaction coefficient (shown at bottom of heat map plot) is calculated by summing over all third- and fourth-order interaction coefficients involving the mutation. e Pairwise interaction coefficients plotted against the distances between the respective alpha-carbons. Mutations are colored by pairwise coefficient as in (d). The Spearman’s rank correlation coefficient (r_s) is indicated in the top-left.
pairwise interaction has been highlighted in earlier work as an instance of compensatory epistasis. Moreover, we identify numerous other interacting mutations, including even stronger positive interactions (along with third and fourth-order effects) between Q498R, G496S, N501Y, and Y505H (Fig. 2d). In fact, the ACE2 affinity is affected by many more significant higher-order interactions, most of which include these four mutations (up to the fifth-order; Supplementary Data 1).

Our epistasis analyses reveal that such high-order compensatory epistasis eliminates the strongly deleterious effects of mutations involved in antibody escape on ACE2 affinity. This compensation between specific beneficial mutations (in particular N501Y) and immune escape mutations has been observed in previous studies. Here, we quantify the extent of this epistasis and hence its impact in shaping the entire RBD sequence-affinity landscape. Specifically, earlier work has shown that five BA.1 mutations (K417N, G446S, E484A, Q493R, and G496S) have a particularly strong effect in promoting antibody escape. These mutations all individually reduce affinity to ACE2 both on average and in the Wuhan Hu-1 background (except E484A; Figs. 1b, 2a, 3a), and the combination of all five is strongly deleterious (Fig. 3a, b). However, strong high-order epistasis with the pair of Q498R and N501Y mitigates this: either N501Y or Q498R alone reduces the cost of the five escape mutations, and the combination of both almost fully compensates for these deleterious effects (Fig. 3b). While these escape mutations do also benefit from interactions with other mutations (Supplementary Fig. 9), N501Y and Q498R account for the majority of the compensatory effect. We note that strong compensatory interactions also mitigate the deleterious effect of Y505H (Fig. 3c). This mutation has not previously been shown to be strongly involved in antibody escape, but the pattern of compensation we observe suggests that it may be functionally relevant in some way.

The extensive epistasis we observe means that the individual effects of each of these 15 mutations, as well as the pairwise interactions between them, are likely different in other viral lineages. However, earlier work has shown that the antibody escape mutations described above (K417N, G446S, E484A, Q493R, and G496S) similarly reduce ACE2 affinity in several other variants (including Alpha, Beta, Eta, and Delta). Consistent with this result, we find that these mutations, along with others that we find have a negative first-order effect on ACE2 affinity, rarely occur across the SARS-CoV-2 phylogeny (Fig. 4a). This suggests that maintaining affinity to human ACE2 is likely an important aspect of viral fitness, so these mutations are typically selected against. Similarly, we find that mutations with negative effects on ACE2 affinity that are compensated by epistatic interactions with N501Y tend to be enriched across the SARS-CoV-2 phylogeny in strains that also have N501Y, relative to strains that do not (Fig. 4b; other pairwise interactions co-occur too rarely to test). This further suggests...
ACE2 af
the accumulation of the many mutations required to both maintain large population sizes and relaxed selection pressures may allow for trast, in chronic infections (e.g. in an immunocompromised host) previously speculated \(^{32,33, BA.1}\) may have evolved within an animal reservoir where selection pressures may also have been relaxed.

Under either scenario, the compensatory mutations may have pre-
ceded the immune escape mutations, minimizing their otherwise deleterious effects on ACE2 affinity. Alternatively, relaxed selection for binding ACE2 may have created a permissive environment for the immune escape mutations, followed by compensation that then allowed the variant to spread to other hosts. Phylogenetic analysis provides some support for the former possibility, as two immune escape mutations (G446S and G496S) occur late in BA.1 evolution (and are not shared with the BA.2 lineage; Supplementary Fig. 10). In addition, a strong selection model based on ACE2 affinity prefers the three BA.1-specific mutations to appear late in the evolution, as observed in the phylogeny (Supplementary Fig. 11). Irrespective of the exact order of mutations, the large viral population size and relaxed selection pressure of a chronic infection may have created conditions conducive to the fixation of the several mutations required for BA.1 to evade neutralizing antibodies while maintaining ACE2 affinity.

We emphasize that our work is confined to 15 mutations within a specific region of one protein, and hence neglects potential interactions with the many other mutations outside of the RBD that are present in the Omicron BA.1 lineage. However, we find that interactions among RBD mutations alone are sufficient to explain how ACE2 affinity is maintained, which is not obvious just from single mutant data. Moreover, we also note that the positive interactions on ACE2 affinity might translate negatively to other phenotypes. For instance, these interactions might inhibit immune escape, and thus, it is necessary to also map the resulting effects of these interactions on immune evasion. We find some hints of this trend in our data. For example, we identify a significant synergistic interaction between S371L, S373P, and S375F that improves RBD expression in yeast, consistent with earlier work showing that this set of mutations is associated with stabilization of a more tightly packed down-conformation of

that at least some of the pairwise epistatic interactions we observe are also present in other backgrounds, and that viral evolution has favored compensation for reduction in ACE2 affinity.

Together, these results suggest that the evolution of antibody escape in BA.1 was possible without disrupting binding to ACE2 because of the compensatory interactions with numerous other mutations unique to this lineage. While signatures of these selection pressures and epistatic interactions are present across the viral phylogeny\(^{28}\), and antibody escape variants could have been compensated by other combinations of mutations, it is only the BA.1 lineage which accumulated this particular combination of interacting compensatory mutations.

Our results also provide insight into why the immune escape phenotype observed in Omicron BA.1 did not arise as the result of mutations accumulating within the then-widely circulating Delta variant. Specifically, the combination of multiple mutations required for both immune escape and maintaining affinity to ACE2 (Fig. 4c) is unlikely to have accumulated within the context of acute infections, which involve few mutations between transmission bottlenecks and presumably strong selection pressures on both functions\(^{29}\). In contrast, in chronic infections (e.g. in an immunocompromised host) large population sizes and relaxed selection pressures may allow for the accumulation of the many mutations required to both maintain ACE2 affinity and evade neutralizing antibodies\(^{30,31}\). Alternatively, as previously speculated\(^{13,14}\), BA.1 may have evolved within an animal reservoir where selection pressures may also have been relaxed. Under either scenario, the compensatory mutations may have pre-
ceded the immune escape mutations, minimizing their otherwise deleterious effects on ACE2 affinity. Alternatively, relaxed selection for binding ACE2 may have created a permissive environment for the

difference in their effect on ACE2 affinity in the presence of N501Y. Error bars indicate standard deviation of effects and are centered on the mean (n=8096 backgrounds). The Spearman’s rank correlation coefficient (r\(_S\)) is indicated in the top-left. (b) Normalized frequency of mutations co-occurring with N501Y across SARS-CoV-2 sequences available on GISAID (calculated based on the frequency at which each mutation occurs on the same branch as N501Y, normalized by their overall frequency; see “Methods”) as a function of the

Fig. 4 | Trajectory of Omicron BA.1 evolution. a Frequency of occurrences for each mutation across SARS-CoV-2 sequences available on GISAID (see “Methods”) as a function of their average effect on ACE2 affinity in our data. Error bars indicate standard deviation of effect sizes and are centered on the mean (n=16384 backgrounds). The Spearman’s rank correlation coefficient (r\(_S\)) is indicated in the top-left. (b) Normalized frequency of mutations co-occurring with N501Y across SARS-CoV-2 sequences available on GISAID (calculated based on the frequency at which each mutation occurs on the same branch as N501Y, normalized by their overall frequency; see “Methods”) as a function of the

Methods

The Spearman's rank correlation coefficient indicates standard deviation of effect sizes and are centered on the mean (n=16384 backgrounds). The Spearman's rank correlation coefficient (r\(_S\)) is indicated in the top-left.
the RBD \( ^{34} \) (Supplementary Fig. 4). Beyond this, numerous other phenotypes are also likely to be relevant.

Despite these caveats, our results demonstrate that key events in viral evolution can depend on high-order patterns of epistasis. We find that these epistatic interactions are nearly entirely synergistic, or compensatory, a pattern that could be a general emerging feature of viruses evolving in immune-constrained landscapes. This may be especially important for complex adaptive events involving numerous mutations, such as immune escape and host-switching. Thus, to predict the future of viral evolution we must move beyond high-throughput screens of single mutations, and more comprehensively analyze combinatorial sequence space. A key challenge is the vastness of this sequence space, which makes exhaustive exploration intractable. However, generating specific combinatorial landscapes like those presented here may help reveal general patterns of epistasis that shape viral evolution in complex environments.

**Methods**

**Yeast display plasmid & strains**

To generate clonal yeast strains for the Wuhan Hu-1 and Omicron BA.1 variants, we cloned the corresponding RBD gblock (IDT, Supplementary Data 2) into pETcon yeast surface-display vector (plasmid 2649; Addgene, Watertown, MA, \#166782) via Gibson Assembly. The sequence in the gblock was codon-optimized for yeast (using the Twist Bioscience algorithm); we found that the codon optimization had a significant impact on display efficiency. Additionally, for the library construction (described below), we deleted two existing BsaI sites from the plasmid by site-directed mutagenesis (Agilent, Santa Clara, CA, \#200521). In the clonal strain production, Gibson Assembly products were transformed into NBT10 beta electrocompetent \( E.\) coli cells (NEB, Ipswich, MA, \#C3020K), following the manufacturer protocol. We isolated plasmids containing the correct sequences into the AWY101 cells as described above. We recovered transformants in a standard plasmid maxiprep (Zymo Research, Irvine, CA, D4201), from the assembly, we introduced the counter-selection marker \( ccdB, \) in place of the fragment insert region, with flanking BsaI sites (Supplementary Data 3). We performed Golden Gate cloning using Golden Gate Assembly Mix (NEB, Ipswich, MA, \#E1601L), following the manufacturer recommended protocol, with a 7:1 molar ratio of the fragment insert pool to plasmid backbone. We transformed the assembly products into NBT10-beta electrocompetent \( E.\) coli cells (L-rom, 0.1 M NaCl) containing 0.3% SeaPrep agarose (VWR, Radnor, PA \#12001–922) spread into a thin layer in a 1 L baffled flask (about 1 cm deep). The mixture was plated at \( 4 \) °C for three hours, after which it was incubated for 18 hr at \( 37 \) °C. We observed a total of 3 million transformants across aliquots. To isolate the plasmid library, we mixed the flasks by shaking for 1 hr and pelleted the cells for standard plasmid maxiprep (2ymo Research, Irvine, CA, D4201), from which we obtained >90 \( \mu \)g of purified plasmid.

We then transformed the purified plasmid library into AWY101 cells as described above. We recovered transformants in a molten SDCAA agarose gel (1.71 g/L YNB without amino acids and ammonium sulfate (Sigma-Aldrich \#Y1251), 5 g/L ammonium sulfate (Sigma-Aldrich \#A4418), 2% dextrose (VWR \#90000–904), 5 g/L Bacto casamino acids (VWR \#223050), 100 g/L ampicillin (VWR \#V0339), 2% Difco Noble Agar (VWR \#90000–774) and incubated at 30 °C for 48 hr. Several colonies were restreaked on SDCAA-agar and again incubated at 30 °C for 48 hr. Clonal yeast strains were picked, inoculated, grown to saturation in liquid SDCAA (6.7 g/L YNB without amino acid (VWR \#90004-150), 5 g/L ammonium sulfate (Sigma-Aldrich \#A4418), 2% dextrose (VWR \#90000–904), 5 g/L Bacto casamino acids (VWR \#223050), 100 g/L ampicillin (VWR \#V0339) containing 0.3% SeaPrep agarose (VWR \#12001–922) spread into a thin layer (about 1 cm deep). The mixture was placed at \( 4 \) °C for three hours, after which it was incubated at 30 °C for 48 hr. From five aliquots, we obtained ~1.2 million colonies. After mixing the flasks by shaking for 1 hr, we grew cells in 5 mL tubes of liquid SDCAA for five generations and stored the saturated culture in 1 mL aliquots supplemented with 5% glycerol at –80 °C.

**High-throughput binding affinity assay (Tite-Seq)**

Tite-Seq was performed as previously described \( ^{36} \). We performed three replicates of the assay on different days. In the first two replicates, a small portion of the library variants contained an off-target mutation (E454W) instead of the intended mutation (E454A). These variants were removed from the data analysis, and in the third replicate the library was supplemented with variants containing the intended mutation (E454A).

**Preparation.** First, we thawed yeast RBD libraries, as well as Wuhan Hu-1 and Omicron BA.1 clonal strains, by inoculating 150 g/ of corresponding glycerol stock (saturated culture with 5% glycerol stored at –80 °C) in 5 mL SDCAA at 30 °C for 20 hr. On the next day, yeast cultures were diluted to OD600 = 0.67 in 5 mL SDBCAA (6.7 g/L YNB without amino acid VWR \#90004-150), 5 g/L ammonium sulfate (Sigma-Aldrich \#A4418), 2% galactose (Sigma-Aldrich \#G0625), 0.1% dextrose (VWR \#90000–904), 5 g/L Bacto casamino acids (VWR \#223050), 1.265 g/L MES buffer (Cayman Chemical, Ann Arbor, MI, \#904) and 5 g/L Bacto casamino acids (Sigma-Aldrich \#Y1251), 2% dextrose (VWR \#90000–904), 5 g/L Bacto casamino acids (VWR \#223050), 100 g/L ampicillin (VWR \#V0339)) at 30 °C, and mixed with 5% glycerol for storage at –80 °C. For dsDNA production by PCR, we designed the fragments such that the mutations they contain are close to the 3' or 5' ends. This design enabled the primers to simultaneously include and introduce the mutations, BsaI sites, and unique overhangs chosen during the PCR. We performed each fragment individually (28 PCR reactions in total; Supplementary Data 3) and pooled the products of each fragment in equimolar ratios. Additionally, we also pooled all 16 purchased DNA duplexes encoding the fifth fragment in equimolar ratios. We then created a final fragment mix by pooling the five fragment pools together. In the Golden Gate reaction, the versions of each fragment would be ligated together in random combinations, producing all of the sequences present at approximately equal frequencies.

In addition to the fragment mix, we prepared four versions of the plasmid backbone for the Golden Gate reaction. Each version contains a combination of the mutations N501Y and S505H. Prior to the assembly, we introduced the counter-selection marker \( ccdB, \) in place of the fragment insert region, with flanking BsaI sites (Supplementary Data 3). We performed Golden Gate cloning using Golden Gate Assembly Mix (NEB, Ipswich, MA, \#E1601L), following the manufacturer recommended protocol, with a 7:1 molar ratio of the fragment insert pool to plasmid backbone. We transformed the assembly products into NBT10-beta electrocompetent \( E.\) coli cells (L-rom, 0.1 M NaCl) containing 0.3% SeaPrep agarose (VWR, Radnor, PA \#12001–922) spread into a thin layer in a 1 L baffled flask (about 1 cm deep). The mixture was placed at \( 4 \) °C for three hours, after which it was incubated for 18 hr at \( 37 \) °C. We observed a total of 3 million transformants across aliquots. To isolate the plasmid library, we mixed the flasks by shaking for 1 hr and pelleted the cells for standard plasmid maxiprep (2ymo Research, Irvine, CA, D4201), from which we obtained >90 \( \mu \)g of purified plasmid.

We then transformed the purified plasmid library into AWY101 cells as described above. We recovered transformants in a molten SDCAA agarose gel (1.71 g/L YNB without amino acids and ammonium sulfate (Sigma-Aldrich \#Y1251), 5 g/L ammonium sulfate (Sigma-Aldrich, St. Louis, MO, \#A4418), 2% dextrose (VWR \#90000–904), 5 g/L Bacto casamino acids (VWR \#223050), 100 g/L ampicillin (VWR \#V0339)) containing 0.3% SeaPrep agarose (VWR \#12001–922) spread into a thin layer (about 1 cm deep). The mixture was placed at \( 4 \) °C for three hours, after which it was incubated at 30 °C for 48 hr. From five aliquots, we obtained ~1.2 million colonies. After mixing the flasks by shaking for 1 hr, we grew cells in 5 mL tubes of liquid SDCAA for five generations and stored the saturated culture in 1 mL aliquots supplemented with 5% glycerol at –80 °C.
100 g/L ampicillin (VWR #0339)), and rotated at room temperature for 16–20 hr.

**Labeling.** After overnight induction, yeast cultures were pelleted, washed twice with 0.01% PBSA (VWR #45001–130; GoldBio, St. Louis, MO, #A-420–50), and resuspended to an OD600 of ~1. A total of 500–700 μL of OD1 yeast cells were labeled with biotinylated human ACE2 (Acrobiosystems #AC2-H2H2E6) at each of the twelve ACE2 concentrations (half-log increments spanning 10.12–5–10.7 M), with volumes adjusted to limit ligand depletion effects to be less than 10% (assuming 50,000 surface RBD/cell37). Yeast-ACE2 mixtures were incubated and rotated at room temperature for 20 hr. Following the incubation, yeast-ACE2 complexes were pelleted by spinning at 3000 × g for 10 min at 4°C, washed twice with 0.5% PBSA + 2 mM EDTA, and subsequently labeled with Streptavidin-RPE (1:100, Thermo Fisher #S866) and anti-cMyc-FITC (1:50, Miltenyi Biotec, Somerville, MA, #130-116-485) at 4°C for 45 min. After this secondary labeling, yeast were washed twice with 0.5% PBSA + 2 mM EDTA and left on ice in the dark until sorting.

**Sorting and recovery.** We sorted the yeast library complex on a BD FACS Aria IIIu, equipped with 405 nm, 440 nm, 488 nm, 561 nm, and 647 nm lasers, and an 85 micron fixed nozzle. To minimize the spectral overlap effects, we determined compensation between FITC and PE using single-fluorophore controls. Single cells were first gated by FSC vs SSC and then sorted by either expression (FITC) or binding (PE) fluorescence. At least one million cells were sorted for each sample. In flow cytometry data to calculate the mean log-fluorescence of bin s at each concentration c, following:

$$F_{s,c} = \sum_b F_{b,c}p_{b,s,c}$$

where $F_{b,c}$ is the mean log-fluorescence of bin b at concentration c, and $p_{b,s,c}$ is the inferred proportion of cells from genotype s that are sorted into bin b at concentration c. The $p_{b,s,c}$ is in turn estimated from the read counts as

$$p_{b,s,c} = \frac{R_{b,s,c} - C_{b,c}}{\sum_b (R_{b,s,c} - C_{b,c})}$$

where $R_{b,s,c}$ is the number of reads from genotype s that are found in bin b at concentration c, whereas $C_{b,c}$ refers to the number of cells sorted into bin b at concentration c.

To propagate the uncertainty in the mean bin estimate, we used the formula

$$\delta F_{s,c} = \sqrt{\sum_b (\delta F_{b,c}p_{b,s,c}^2 + F_{b,c}^2 \delta p_{b,s,c}^2)}$$

where $\delta F_{b,c}$ is the spread of log fluorescence of cells sorted into bin b at concentration c. As previously investigated, we found that estimating $\delta F_{s,c}$ is sufficient to capture the variation we observed in log-fluorescence within each bin. In contrast, the error in $p_{b,s,c}$ emerges from the sampling error, which can be approximated as a Poisson process when read counts are high enough.

Thus we have:

$$\delta p_{b,s,c} = \frac{p_{b,s,c}}{\sqrt{R_{b,s,c}}}$$

Finally, we inferred the binding dissociation constant ($K_{D,b}$) for each variant by fitting the logarithm of Hill function to the mean log-
fluorescence $F_{s,c}$ as a function of ACE2 concentrations $c$:

$$F_{s,c} = \log_{10} \left( \frac{c}{c + K_{Ds}} A_s + B_s \right).$$

where $A_s$ is the increase in fluorescence at ACE2 saturation, and $B_s$ is the background fluorescence level. The fit was performed using the curve_fit function in the Python package scipy.optimize. Across all genotypes, we gave reasonable bounds on the values of $A_s$ to be $10^{-10}$, $B_s$ to be $10^0$, and $K_{Ds}$ to be $10^{-14}$–$10^{-5}$. We then averaged the inferred $K_{Ds}$ values across the three replicates after removing values with poor fit ($r^2 < 0.8$).

We note that our approach here differs slightly from some earlier work which often fits this Hill function directly using the mean bin with the following equation:

$$\sum bp_{b,c} = \log_{10} \left( \frac{c}{c + K_{Ds}} A_s + B_s \right)$$

rather than using the inferred mean fluorescence values. This use of average bin values introduces bias because the bin numbers are proportional to mean log-fluorescence, rather than to mean fluorescence. Hence the $K_{Ds}$ values inferred with this earlier method are not exact. However, in our measurement range, these values are still linearly correlated to our measurements (see Supplementary Fig. 1e).

**Isogenic measurements for validation**

We validated our high-throughput binding affinity method by selecting 10 specific RBD clones for lower-throughput validation: Wuhan Hu-1, Omicron, 5 single-mutants (K417N, S477N, T478K, Q498R, N501I), two double mutants (Q498R/N501Y and E484A/Q498R), one genotype with four mutations (K417N/E484A/Q498R/N501Y). For each isogenic titration curve, we followed the same labeling strategy, titrating ACE2 at concentrations ranging from $10^{-12}$–$10^{-7}$ M for isogenic yeast strains that display only the sequence of interest. The mean log fluorescence was measured using a BD LSR Fortessa cell analyzer. We directly computed the mean and variances of these distributions for each concentration and used them to infer the value of $-\log_{10}(K_{Ds})$ using formula (shown above) (see Supplementary Fig. 1).

**Epistasis analysis**

We first used a simple linear model where the effects of combinations of mutations sum to the phenotype of a sequence. The logarithm of the binding affinity $\log_{10}(K_{Ds})$ is proportional to free energy changes, hence in a model without interaction, they would combine additively. The full K-order model can be written:

$$-\log_{10}(K_{Ds}) = \beta_0 + \sum_{i=1}^{K} \sum_{c_{ci}} \beta_c x_{c,i},$$

where $\beta_c$ denotes the coefficient for the combination of mutation $c$ (either single-mutation coefficient for $i = 1$ or interaction coefficient otherwise), contains all combinations of $i$ mutations and is equal to 1 if the sequence contains all the mutations in and to 0 otherwise. This choice is called ‘biochemical’ or ‘local’ epistasis and is the one used in the main text. Another option, called ‘statistical’ or ‘ensemble’ epistasis, consists of replacing the coefficients by. In this “statistical” model, the baseline is the mean affinity of the population and the first-order effects of the mutations correspond to their mean effect on affinity. We present the result of this analysis, and the differences with the biochemical model, in Supplementary Fig. 6.

To choose the optimal value of $K$, we follow the method detailed in Phillips and Lawrence et al., 2021. Briefly, we use 10-fold cross-validation to test all values of $K \leq 6$. For each value of $K$, the data is split into ten and each of the ten sub-dataset is used as a test set for a model trained on the rest of the data. We chose the value of $K$ that maximizes the prediction performance ($R^2$) averaged over all ten testing datasets. For this dataset we found an optimal value of $K = 5$ (Supplementary Fig. 5). Finally, we trained a $K=5$ model over the complete dataset to get the final coefficients. The number of parameters of the final model (50000) is much lower than the number of observed data points ($2^{11} = 32768$).

As mentioned above, the logarithm of binding affinity is proportional to a free energy change, an extensive quantity. This theoretically justifies the use of a linear model. Nonetheless, in some scenarios, the interactions between mutations can be better explained by a nonlinear function with few parameters acting on the full phenotype (“global epistasis”) rather than a large number of small-effects interactions at high order (“idiosyncratic epistasis”). Our implementation is similar to that described by Sailer and Harms, 2017 and follows closely Phillips and Lawrence et al., 2021. In short, we use a logistic function $\Phi$, with four parameters, to fit the expression:

$$-\log_{10}(K_{Ds}) = \Phi \left( \beta_0 + \sum_{i=1}^{K} \sum_{c_{ci}} \beta_c x_{c,i} \right),$$

with $\Phi(y) = \frac{A}{1 + e^{y - \mu}^{\phi/\sigma}} + B$.

The choice of a logistic function is justified by the general form of $K_{D,app}$ distribution, which slightly “plateaued” at strong $K_{D,app}$. This effect is not caused by experimental artifacts (Supplementary Fig. 3) but instead by a form of “diminishing returns” epistasis. Practically, the parameters are inferred by fitting successively the additive $\beta$ and the nonlinear function parameters. Although the global epistasis transformation does improve the fit, the additive coefficients observed at low order do not change significantly (Supplementary Fig. 7).

**Structural analysis**

We used the reference structure of a 2.79 Å cryo-EM structure of Omicron BA.1 complexed with ACE2 (PDB ID: 7WPB). In Fig. 2c, the contact surface area is determined by using Chimera’s to measure the buried surface area between ACE2 and each mutated residue in the RBD (measure buried area function, default probeRadius of 1.4 Å). In Fig. 2E, the distance between $\alpha$-carbons is measured using PyMol.

**Order of mutations**

ACE2 binding affinity impacts the fitness of SARS-CoV-2 variants and can thus be leveraged to partially infer its past trajectory. This piece of information is particularly important for Omicron BA.1, where phylogenetic information is limited. Because our dataset contains the ACE2 affinity of all possible evolutionary intermediates, we can infer the likelihoods of all pathways between the ancestral Wuhan Hu-1 sequence and Omicron BA.1. To do this we need to choose a selection model. The circumstances in which the Omicron variant evolved are unknown, and the evolutionary fitness of the virus is more complex than its capacity to bind ACE2 – immune pressure, structural stability, and expression level also play a role, among many other factors. In addition, back-mutations are common in viral evolution and selection pressure can change depending on whether the strain is switching hosts rapidly or part of a long-term infection. Here, we have chosen to adopt an extremely simple weak-mutation/strong-selection regime of viral evolution.

In that model, selection proceeds as a Markov process, where the population is characterized by a single sequence that acquires a single mutation at each discrete time step. We assume that back mutations (i.e. a residue changing from the Wuhan Hu-1 amino-acid to the BA.1 one) are not possible. Once such a sequence is generated, it will either fix in the full population or die out. The important parameter is then the fixation probability, which depends on the binding affinity of both the original and mutated sequences. We choose to use the commonly used...
classical fixation probability\(^\text{48}\), for a mutation with selection coefficient \(a\) in a population of size \(N\):

\[
\phi_{fix}(a, N) = \frac{1 - e^{-a}}{1 + e^{-aN}}
\]

(10)

Here, the selection coefficient \(a\) is proportional to the difference in log binding affinities between the two sequences. We use this model in the “strong selection” limit \((N \to \infty\) and \(a \to \infty\)), where a mutation fixes if it is advantageous or if it is the less deleterious choice among all the leftover mutations. Weaker selection models, with lower values of \(a\) and \(N\), give qualitatively similar results provided the selection pressure is high enough (see Supplementary Fig. 11b; for small enough selection pressures the order becomes random as expected). To implement this model, we use a transition matrix approach that allows us to quickly compute the probability that each residue appears at a specific position. To verify that the order of specific mutations is statistically significant we use a bootstrap method and sample affinity values from normal distributions with mean and standard deviation given by our experimental measurements. We then sample mutations according to the model described previously and use standard methods to determine significance.

**Force directed layout**

The high-dimensional binding affinity landscape can be projected in two dimensions with a force-directed graph layout approach (see https://desai-lab.github.io/wuhan_to_omicron/). Each sequence in the antibody library is a node, connected by edges to its single-mutation neighbors. An edge between two sequences s and t is given the weight:

\[
\omega_{st} = \frac{1}{0.01 + \log_{10}(K_{D, s} - K_{D, t})}
\]

(11)

In a force-directed representation, nodes repel each other, while the edges pull together the nodes they are attached to. In our scenario, this means that nodes with a similar genotype (a few mutations apart) and a similar phenotype (binding affinity) will be close to each other in two dimensions. Importantly this is not a “landscape” representation: the distance between two points is unrelated to how easy it is to reach one genotype from another in a particular selection model. Practically, after assigning all edge weights, we use the layout function `layout_drl` from the Python package `igraph`, with default settings, to obtain the layout coordinates for each variant.

**Genomic data**

To analyze SARS-CoV-2 phylogeny (Fig. 4a, b), we used all complete RBD sequences from all SARS-CoV-2 genomes deposited in the Global Initiative on Sharing All Influenza Data (GISAID) repository\(^\text{48}\) with the GISAID Audacity global phylogeny (EPI SET ID: EPISSET_20220615uq) available on GISAID up to June 15, 2022, and accessible at https://doi.org/10.55876/gis8.220615uq. We pruned the tree to remove all available on GISAID up to June 15, 2022, and accessible at https://doi.org/10.55876/gis8.220615uq. GISAID Audacity global phylogeny (EPI SET ID: EPI_SET_20220615uq), we pruned the tree to remove all available on GISAID up to June 15, 2022, and accessible at https://doi.org/10.55876/gis8.220615uq. We pruned the tree to remove all available on GISAID up to June 15, 2022, and accessible at https://doi.org/10.55876/gis8.220615uq. We pruned the tree to remove all available on GISAID up to June 15, 2022, and accessible at https://doi.org/10.55876/gis8.220615uq. We pruned the tree to remove all available on GISAID up to June 15, 2022, and accessible at https://doi.org/10.55876/gis8.220615uq. We pruned the tree to remove all available on GISAID up to June 15, 2022, and accessible at https://doi.org/10.55876/gis8.220615uq.

**Statistical analyses and visualization**

All data processing and statistical analyses were performed using R (v4.1.0\(^\text{41}\)) and python (3.10.0\(^\text{41}\)). All figures were generated using ggplot2\(^\text{45}\) and matplotlib\(^\text{46}\).

**Reporting summary**

Further information on research design is available in the Nature Portfolio Reporting summary linked to this article.

**Data availability**

The Raw sequencing reads generated in this study have been deposited in the NCBI BioProject database under accession number PRJN849979. The github repository\(^\text{39}\) https://github.com/desai-lab/compensatory_epistasis_omicron/ contains all associated metadata (Titeseq/metadata and the flow cytometry fcs files (Titeseq/facs-data)). We also used a publicly available third party dataset from GISAID, accessible at https://doi.org/10.55876/gis8.220615uq.

**Code availability**

The Github repository\(^\text{39}\) https://github.com/desai-lab/compensatory_epistasis_omicron/Titeseq/ contains all associated analysis codes.

**References**

1. Viana, R. et al. Rapid epidemic expansion of the SARS-CoV-2 Omicron variant in southern Africa. Nature 603, 679–686 (2022).
2. Dejnirattisai, W. et al. SARS-CoV-2 Omicron-B.1.1.529 leads to widespread escape from neutralizing antibody responses. Cell 185, 467–484.e15 (2022).
3. Cameroni, E. et al. Broadly neutralizing antibodies overcome SARS-CoV-2 Omicron antigenic shift. Nature 602, 664–670 (2022).
4. Cao, Y. et al. Omicron escapes the majority of existing SARS-CoV-2 neutralizing antibodies. Nature 602, 657–663 (2022).
5. Liu, L. et al. Striking antibody evasion manifested by the Omicron variant of SARS-CoV-2. Nature 602, 676–681 (2022).
6. Planas, D. et al. Considerable escape of SARS-CoV-2 Omicron to antibody neutralization. Nature 602, 671–675 (2022).
7. Mannar, D. et al. SARS-CoV-2 Omicron variant: Antibody evasion and cryo-EM structure of spike protein-ACE2 complex. Science 375, 760–764 (2022).
8. Starr, T. N. et al. Shifting mutational constraints in the SARS-CoV-2 receptor-binding domain during viral evolution. bioRxiv https://doi.org/10.1101/2022.02.24.481899 (2022).
9. Starr, T. N. et al. Deep mutational scanning of SARS-CoV-2 receptor binding domain reveals constraints on folding and ACE2 binding. Cell 182, 1295–1310.e20 (2020).
10. Wu, L. et al. SARS-CoV-2 Omicron RBD shows weaker binding affinity than the currently dominant Delta variant to human ACE2. Sig. Transduct. Target 7, 8 (2022).
11. Han, P. et al. Receptor binding and complex structures of human ACE2 to spike protein from omicron and delta SARS-CoV-2. Cell 185, 630–640.e10 (2022).
12. Greaney, A. J. et al. Comprehensive mapping of mutations in the SARS-CoV-2 receptor-binding domain that affect recognition by polyclonal human plasma antibodies. Cell Host Microbe 29, 463–476.e6 (2021).
13. Adams, R. M., Mora, T., Walczak, A. M. & Kinney, J. B. Measuring the sequence-affinity landscape of antibodies with massively parallel titration curves. Elife 5, (2016).
14. Phillips, A. M. et al. Binding affinity landscapes constrain the evolution of broadly neutralizing anti-influenza antibodies. *Elife* **10**, (2021).
15. Adams, R. M., Kinney, J. B., Walczak, A. M. & Mora, T. Epistasis in a fitness landscape defined by antibody-antigen binding free energy. *Cell Syst.* **8**, e6–93.e3 (2019).
16. McCallum, M. et al. Structural basis of SARS-CoV-2 Omicron immune evasion and receptor engagement. *Science* **375**, 864–868 (2022).
17. Greaney, A. J. et al. Mapping mutations to the SARS-CoV-2 RBD that escape binding by different classes of antibodies. *Nat. Commun.* **12**, 4196 (2021).
18. Greaney, A. J., Starr, T. N. & Bloom, J. D. An antibody-escape calculator for mutations to the SARS-CoV-2 receptor-binding domain. *bioRxiv* [https://doi.org/10.1101/2021.12.04.471236] (2021).
19. Sailer, Z. R. & Harms, M. J. High-order epistasis shapes evolutionary trajectories. *PLoS Comput. Biol.* **13**, e1005541 (2017).
20. Wells, J. A. Additivity of mutational effects in proteins. *Biochemistry* **29**, 8509–8510 (1990).
21. Olson, C. A., Wu, N. C. & Sun, R. A comprehensive biophysical description of pairwise epistasis throughout an entire protein domain. *Curr. Biol.* **24**, 2643–2651 (2014).
22. Ottowinowski, J., McCandlish, D. M. & Plotkin, J. B. Inferring the shape of global epistasis. *Proc. Natl Acad. Sci. USA* **115**, E7550–E7558 (2018).
23. Starr, T. N. & Thornton, J. W. Epistasis in protein evolution. *Protein Sci.* **25**, 1204–1218 (2016).
24. Zahradník, J. et al. SARS-CoV-2 variant prediction and antiviral drug design are enabled by RBD in vitro evolution. *Nat. Microbiol.* **6**, 1188–1190 (2021).
25. Laffeber, C., de Koning, K., Kanaar, R. & Lebbink, J. H. G. Experimental evidence for enhanced receptor binding by rapidly spreading SARS-CoV-2 variants. *J. Mol. Biol.* **433**, 167058 (2021).
26. Rochman, N. D. et al. Epistasis at the SARS-CoV-2 receptor-binding domain interface and the propitiously boring implications for vaccine escape. *MBio* **13**, e0013522 (2022).
27. Javanmard, K. et al. Antibody escape and cryptic cross-domain stabilization in the SARS-CoV-2 Omicron spike protein. *bioRxiv* [https://doi.org/10.1101/2022.04.18.488614] (2022).
28. Rochman, N. D. et al. Ongoing global and regional adaptive evolution of SARS-CoV-2. *Proc. Natl. Acad. Sci. USA* **118**, (2021).
29. Lythgoe, K. A. et al. SARS-CoV-2 within-host diversity and transmission. *Science* **372**, eabg0821 (2021).
30. Kemp, S. A. et al. SARS-CoV-2 evolution during treatment of chronic infection. *Nature* **592**, 277–282 (2021).
31. Choi, B. et al. Persistence and evolution of SARS-CoV-2 in an immunocompromised host. *N. Engl. J. Med.* **383**, 2291–2293 (2020).
32. Hale, V. L. et al. SARS-CoV-2 infection in free-ranging white-tailed deer. *Nature* **602**, 481–486 (2022).
33. Bate, N. et al. In vitro evolution predicts emerging CoV-2 mutations with high affinity for ACE2 and cross-species binding. *bioRxiv* [https://doi.org/10.1101/2021.12.33.473975] (2021).
34. Gobeil, S. M.-C. et al. Structural diversity of the SARS-CoV-2 Omicron spike. *Mol. Cell* **82**, 2050–2068.e6 (2022).
35. Wentz, A. E. & Shusta, E. V. A novel high-throughput screen reveals yeast genes that increase secretion of heterologous proteins. *Appl. Environ. Microbiol.* **73**, 1189–1198 (2007).
36. Gietz, R. D. & Schiestl, R. H. Quick and easy yeast transformation using the LiAc/SS carrier DNA/PEG method. *Nat. Protoc.* **2**, 35–37 (2007).
37. Boder, E. T. & Wittrup, K. D. Yeast surface display for screening combinatorial polypeptide libraries. *Nat. Biotechnol.* **15**, 553–557 (1997).
38. Nguyen Ba, A. N. et al. High-resolution lineage tracking reveals travelling wave of adaptation in laboratory yeast. *Nature* **575**, 494–499 (2019).
39. Moulana, A. et al. deslai-lab/compensatory_epistasis_omicron. [Zenodo, 2022]. [https://doi.org/10.5281/zenodo.7235104].
40. Barnett, M. Regex. Preprint at (2013).
41. Sailer, Z. R. et al. Prospective mapping of viral mutations that escape antibodies used to treat COVID-19. *Science* **371**, 850–854 (2021).
42. Poelwijk, F. J., Krishna, V. & Ranganathan, R. The context-dependence of mutations: A linkage of formalisms. *PLoS Comput. Biol.* **12**, e1004771 (2016).
43. Sailer, Z. R. & Harms, M. J. Detecting high-order epistasis in nonlinear genotype-phenotype maps. *Genetics* **205**, 1079–1088 (2017).
44. Pettersen, E. F. et al. UCSF ChimeraX: Structure visualization for researchers, educators, and developers. *Protein Sci.* **30**, 70–82 (2021).
45. Schrodinger, L. L. C. The PyMOL Molecular Graphics System, (2015).
46. Upadhyay, V., Patrick, C., Lucas, A. & Mallela, K. M. G. Convergent evolution of multiple mutations improves the viral fitness of SARS-CoV-2 variants by balancing positive and negative selection. *Biochemistry* **61**, 963–980 (2022).
47. Kryazhimskiy, S., Dushoff, J., Bazykin, G. A. & Plotkin, J. B. Prevalence of epistasis in the evolution of influenza A surface proteins. *PLoS Genet.* **7**, e1001301 (2011).
48. Kimura, M. On the probability of fixation of mutant genes in a population. *Genetics* **47**, 713–719 (1962).
49. Khare, S. et al. GISAID's role in pandemic response. *China CDC Wky* **3**, 1049–1051 (2021).
50. Elbe, S. & Buckland-Merrett, G. Data, disease and diplomacy: GISAID’s innovative contribution to global health. *Glob. Chall.* **1**, 33–46 (2017).
51. Shu, Y. & McCauley, J. GISAID: Global initiative on sharing all influenza data – from vision to reality. *Euro Surveill.* **22**, (2017).
52. Huerta-Cepas, J., Serra, F. & Bork, P. ETE 3: Reconstruction, analysis, and visualization of phylogenomic data. *Mol. Biol. Evol.* **33**, 1635–1638 (2016).
53. R Core Team. R: A language and environment for statistical computing. (2017).
54. Van Rossum, G. & Drake, F. L. Python 3 Reference Manual. (CreateSpace, 2009).
55. Wickham, H. *ggplot2*. (Springer International Publishing, 2016).
56. Hunter, J. D. *Matplotlib*: A 2D graphics environment. *Comput. Sci. Eng.* **9**, 90–95 (2007).
Author contributions
Conceptualization: A.M., T.D., A.M.P., J.C., T.N.S., A.J.G., J.D.B., and M.M.D. Methodology: A.M., T.D., A.M.P., J.C., S.N., T.N.S., and A.J.G. Library design and production: A.M., T.D., A.M.P., J.C., and A.J.G. Experiments: A.M., T.D., A.M.P., J.C., and A.A.R. Validation: A.M., T.D., A.M.P., J.C., S.N., and T.N.S. Data analysis: A.M., T.D., A.M.P., J.C., S.N., and T.N.S. Supervision: A.M.P., J.D.B., and M.M.D. Funding acquisition: J.D.B. and M.M.D. Writing—original draft: A.M., T.D., A.M.P., J.C., and M.M.D. All the authors reviewed and edited the manuscript.

Competing interests
A.M.P. and M.M.D. have or have recently consulted for Leyden Labs. J.D.B. has or has recently consulted for Apriori Bio, Oncorus, Moderna, and Merck. J.D.B., A.J.G., and T.N.S. are inventors on Fred Hutch licensed patents related to viral deep mutational scanning. The other authors declare no competing interests.

Additional information
Supplementary information The online version contains supplementary material available at https://doi.org/10.1038/s41467-022-34506-z.

Correspondence and requests for materials should be addressed to Angela M. Phillips or Michael M. Desai.